We believe that cardiovascular health should be accessible to everyone, everywhere.
Reduce the gap in arrhythmia diagnosis worldwide
In the world, 100 million tests are not carried out every year. 1, 2, 3
In Brazil: 20 million people have arrhythmias, only 2 million are diagnosed each year. 12, 13, 14
Quoretech exists to eliminate the delays, inaccessibility, and inaccuracies in arrhythmia diagnosis, saving lives and improving quality of care for millions worldwide.
How can we transform the cardiovascular diagnosis journey?
Advanced and accessible technology at the point of service.
A complete platform powered by AI.
Scalable business model with no initial investment required
Greater patient satisfaction: NPS of 95.9.
Our beliefs
People first
We prioritize patients, partners, and team members in all cecisions an actions.
Think big – think daring
We aim for transformative impact, challenging traditional models with innovative solutions
Endless improvement
We embrace a mindset of continuous learning, iteration, and excellence across all operations.
Quick learning
We adapt rapidly by learning from data, feedback, successes, and failures.
Key moments
We recognize and honor milestones and achievements, reinforcing a positive and motivated culture.
Simplicity
Design products, processes, and communications to be intuitive, efficient, and user-friendly, avoiding unnecessary complexity.
References
1. Worldometer, Current World Population, disponível em: [https://www.worldometers.info/world-population/], acesso em 25Abr2025
2. Karamitanha F., et al, Difference Between Various Countries in Mortality and Incidence Rate of the Atrial Fibrillation Based on Human Development Index in Worldwide: Data From Global Burden of Disease 2010-2019, Current Problems in Cardiology Volume 48, Issue 1, January 2023, 101438
3. Van Gelder I. C, et al, 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS), European Heart Journal (2024) 00, 1-101, https://doi.org/10.1093/eurheartj/ehae176 and Risks, 1990-2022100000.
4.Known S., et al, Comparison Between the 24-hour Holter Test and 72-hour Single-Lead Electrocardiogram Monitoring With an Adhesive Patch-Type Device for Atrial Fibrillation Detection: Prospective Cohort Study, J Med Internet Res. 2022 May; 24(5): e37970. Published online 2022 May 9. doi:
10.2196/37970: 10.2196/37970.
5. Kim J. Y., et al, The efficacy of detecting arrhythmia is higher with 7-day continuous electrocardiographic patch monitoring than with 24-h Holter monitoring, Journal of Arrhthmia, Received: 3 January 2023 | Revised: 13 April 2023 | Accepted: 20 April 2023, DOI: 10.1002/joa3.12865.
6. Cadastro Nacional de Estabelecimentos de Saúde (CNES), Consulta Estabelecimentos, Nome com “COR” ou “CARDIO”, mediana dos estabelecimentos, disponível em: [https://cnes.datasus.gov.br/], acesso em 02Maio2025.
7. Hospital Israelita Albert Einsteim, A Comparative study of an innovative 3-lead wireless water resistant Holter system and a conventional Holter system, disponível em: [https://clinicaltrials.gov/study/NCT04723355?term=Quoretech&rank=1]; acesso em
8. Data on File, Quoretech Jul/21 onde 44,4%
9. Yenikomshian M., et al, Cardiac arrhythmia detection outcomes among patients monitored with the Zio patch system: a systematic literature review, Curr Med Res Opin. 2019 Oct;35(10):1659-1670. doi: 10.1080/03007995.2019.1610370. Epub 2019 May 28.
10. Leclercq C., et al, Wearables, telemedicine, and artificial intelligence in arrhythmias and heart failure: Proceedings of the European Society of Cardiology Cardiovascular Round Table, EP Europace, Volume 24, Issue 9, September 2022, Pages 1372-1383, https://doi.org/10.1093/europace/euac05
11. ROL_ANS, disponível em: [https://www.ans.gov.br/ROL-web/pages/cobertura.xhtml], acesso em: 25Abr2025
12. SOBRAC, A vida de um portador de arrimtia cardíaca, disponível em: [https://sobrac.org/publico-
geral/sdrfvesfvs/], acesso em 25Abr2025
13. ANS, Procedimentos 2023, disponível em: [https://app.powerbi.com/view?r=eyJrIjoiNzIxNz|4MjItZTEwNyO0NmQ2LTk3ZTktZDNjYjA5Zjk2MTIOliwid
Cl6ljlkYmEOODBjLTRmYTctNDJmNC1iYmEzLTBmYjEzNzVmYmU1ZiJ9], acesso em 25Abr2025
14. DATASUS, PRODUÇÃO AMBULATORIAL DO SUS – BRASIL – POR LOCAL DE ATENDIMENTO, HOLTER, disponível em: [http://tabnet.datasus.gov.br/cgi/tabcgi.exe?sia/cnv/qabr.def], acesso em 25Abr2025
